papasnewshoes
Posted - 02/27/24
$VKTX wow was in this a long time ago, congrats to the longs who held. Missed out on the real gains just like I missed out by selling $BLU too early. Instead I sold and bought a weed stock, worse trading decision ever.
bhas007
Posted - 12/18/23
$BLU when hfs wantedly reducing share price how public knowingly purchase these shares . It's absurd
kokooo
Posted - 11 months ago
$BLU RIGL-cancer deal upgrade to 15$ ,got 2 drugs on the market ,stock so cheap its insane trade at 1.29E
Lavin1
Posted - 11 months ago
$JBLU Crooks MM are pinning this, will not succeed for long. Go $BLU!
PagingDrJayTrotter
Posted - 1 year ago
$CRSP $BLU to buy more or not to buy more that is the question… good luck in what ever you decide
stockilluminati
Posted - 1 year ago
$BLU https://clinicaltrials.gov/study/NCT06085209 - trial update posted here!
Quantisnow
Posted - 1 year ago
$BLU 📜 SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)
https://quantisnow.com/i/4895970?utm_source=stocktwits
45 seconds delayed.
tickeron
Posted - 1 year ago
$AADI vs. $BLU: what will be the best investment? #AadiBioscience https://srnk.us/go/4827933
xenomorph777
Posted - 1 year ago
@Jcouncil8 these are all still fairly early studies and those data will provide high-level signal since the N won't be large, so they don't offer much leverage IMO. Chronic cough only works in our favor due to the recent $BLU acquisition but a more robust study is still needed to confirm the preliminary signal it presented in June. What's awesome is that 629 has already proven itself as a next-gen RASP asset in other indications (chronic cough) outside of DED/AC so a buyer should still be able to acquire a fair amount of confidence of its potential without waiting for robust datasets 1-2 years from now
xenomorph777
Posted - 1 year ago
@prognonymous @xemite unfortunately, no one will pay us for the systemic pipeline today because it is simply far too early but we can certainly get additional premium for chronic cough due to the recent $BLU acquisition. Our BO valuation will be primarily driven by DED/AC plus about 500M-1B for chronic cough if we’re lucky. If no outright BO, the solution you propose is certainly elegant Xemite and I’d be onboard, but I just don’t think Todd is looking to work for any longer than he has to. He’s a VC by trade and will stay on to lead the transition (per cancelled equity acceleration rights) but I think he wants to go live his life afterward. Again, this is all simply my opinion based off of my qualitative observations during calls/presentations. What’s for certain is that a traditional partnership would be a big nothingburger for both Aldeyra and its shareholders.
kirkulr
Posted - 1 year ago
@Easytrends @Kosmos709 @Rasputinostradamus And I don’t have the patience, I had $BLU last year. I did my DD, bought the dips at 4-5? Don’t remember. It took a year or more to be sold for 15$ a share.
Quantisnow
Posted - 1 year ago
$BLU 📜 SEC Form 15-12G filed by BELLUS Health Inc.
https://quantisnow.com/i/4734090?utm_source=stocktwits
45 seconds delayed.
tickeron
Posted - 1 year ago
$BLU vs. $MPC: what is the best stock to add to your portfolio? #BELLUSHealth https://srnk.us/go/4782463
xenomorph777
Posted - 06/30/23
@Kingjake26 @johnnygogogo @VoxGeorge they need more data - i think the Phase 3 will blow $BLU out of the water based off the Phase 2 data and so does the street, hence why I added 1B as a floor in fair value. We'll see how the cards play out but 3B is guaranteed for outright sale. Reproxalap is our valuation and our valuation is reproxalap. Everything else is a cherry on top! Should be a great year my friends
Jolierebel
Posted - 06/29/23
$BLU
Keyurdesai860
Posted - 06/29/23
$BLU what happened with BLU today.? Has it been delisted? Did we loose our money.?
Botmantrade
Posted - 06/29/23
$BLU WHY IS THIS BEEN HALTED?? SOMEBODY PLEASE TELL ME
xenomorph777
Posted - 06/29/23
$ALDX Bingo. RASP modulators (reproxalap, 629, 246, 248) are our bread and butter. 2191 is not a RASP modulator, but offers upside to our fair value if it proves useful in any of its target indications. Remember, any interested buyer will be acquiring us for our RASP platform. That is what sets us apart from every other inflammatory/immunology company out there. That being said, reproxalap is still the only RASP asset that is driving 90-95% of our fair value. The other RASP assets are far too early but 629 may now provide a valuation bump via chronic cough, due to the recent 2B $BLU acquisition by $GSK.
Quantisnow
Posted - 06/28/23
$BLU 📜 SEC Form S-8 POS filed by BELLUS Health Inc.
https://quantisnow.com/i/4698941?utm_source=stocktwits
45 seconds delayed.
Quantisnow
Posted - 06/28/23
$BLU 📜 SEC Form S-8 POS filed by BELLUS Health Inc.
https://quantisnow.com/i/4698662?utm_source=stocktwits
45 seconds delayed.
EarningsInsider
Posted - 06/28/23
BELLUS Health Inc. Files SEC Form 6-K $BLU https://www.marketbeat.com/stocks/NASDAQ/BLU/sec-filings/
Quantisnow
Posted - 06/28/23
$BLU 📜 SEC Form 6-K filed by BELLUS Health Inc.
https://quantisnow.com/i/4697291?utm_source=stocktwits
45 seconds delayed.
xenomorph777
Posted - 06/28/23
$ALDX After 629 data in CC, our fair value is at least 4B for outright sale today IMO. CC delivered huge and increased our fair value by 1B, which is fair and may even be conservative considering $BLU was just acquired for 2B and currently looking inferior to our asset. Let’s see what 2191’s RP data has in store for us. Remember, nothing but pure upside. Can’t impact reproxalap cashflow so it offers no downside to our fair value.
xenomorph777
Posted - 06/28/23
$ALDX 629 had the same efficacy profile and in harder-to-treat patients. We also accomplished all this in two weeks and with a significant safety advantage. The study wasn’t even powered for efficacy as a primary endpoint and we still crushed it. Now imagine how we’d fare in a Phase 3 study that is powered for efficacy and will be for 3 months instead of 2 weeks. We’ll blow $BLU out of the water. I don’t think Aldeyra will be around to see that data 😉
EarningsInsider
Posted - 06/28/23
BELLUS Health Inc. Files SEC Form 6-K $BLU https://www.marketbeat.com/stocks/NASDAQ/BLU/sec-filings/
xenomorph777
Posted - 06/28/23
$ALDX 629 is better than $BLU and everyone (including analysts) know this. CC data sealed the deal by validating 629 as the near-mid term future of reproxalap and the RASP platform. This is why I now believe an outright BO is more likely than a reproxalap carveout.
Quantisnow
Posted - 06/28/23
$BLU 📜 SEC Form 6-K filed by BELLUS Health Inc.
https://quantisnow.com/i/4695951?utm_source=stocktwits
45 seconds delayed.
Quantisnow
Posted - 06/28/23
$BLU $GSK 📰 Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health
https://quantisnow.com/i/4695849?utm_source=stocktwits
45 seconds delayed.
xenomorph777
Posted - 06/27/23
@peterv9962 we are better than $BLU - it doesn’t take a genius to figure that out! I bet $GSK are grinding their teeth for shelling out 2B to acquire BLUE a few weeks too early!